3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
1
Conditions
Recurrence
1
Lymphoma, Mantle-Cell
1
Interventions
pembrolizumab
30
Cisplatin
20
Carboplatin
20
Paclitaxel
18
Dexamethasone
15
Pemetrexed
13
Nivolumab
13
Ipilimumab
12
Fluorouracil
11
Cyclophosphamide
11
Gemcitabine
10
Trastuzumab
9
Docetaxel
9
Cytarabine
9
daratumumab
8
atezolizumab
8
Rituximab
8
Capecitabine
8
Lenalidomide
7
Doxorubicin
7
zanubrutinib
6
Prednisone
6
Daunorubicin
6
Bortezomib
6
venetoclax
5
trametinib
5
nilotinib
5
ibrutinib
5
fludarabine
5
dabrafenib
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Has announcements
×
brexucabtagene autoleucel
×
Clear all
NCT02601313
2026-03-18
ZUMA-2
Gilead Sciences
Phase 2
Completed
105 enrolled
33 charts
1 FDA
NCT02614066
2024-11-19
ZUMA-3
Gilead Sciences
Phase 1/2
Completed
125 enrolled
27 charts
1 FDA